2014
DOI: 10.1177/1759720x14523500
|View full text |Cite
|
Sign up to set email alerts
|

The osteocyte as a therapeutic target in the treatment of osteoporosis

Abstract: Abstract:Osteoporosis is characterized by a low bone-mineral density associated with skeletal fractures. The decrease in bone-mineral density is the consequence of an unbalanced bone-remodeling process, with higher bone resorption than bone formation. The orchestration of the bone-remodeling process is under the control of the most abundant cell in bone, the osteocyte. Functioning as an endocrine cell, osteocytes are also a source of soluble factors that not only target cells on the bone surface, but also targ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
34
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 32 publications
(35 citation statements)
references
References 132 publications
1
34
0
Order By: Relevance
“…Calcium‐sensing receptors present in parathyroid gland, kidney, osteoblasts, and osteocytes influence the release of PTH as well as the calcium homeostasis. Calcilytic drugs act as antagonists to calcium‐sensing receptors . Extracellular calcium activates the calcium‐sensing receptors to regulate the PTH secretion in parathyroid cells.…”
Section: Current Osteoporosis Treatmentmentioning
confidence: 99%
See 1 more Smart Citation
“…Calcium‐sensing receptors present in parathyroid gland, kidney, osteoblasts, and osteocytes influence the release of PTH as well as the calcium homeostasis. Calcilytic drugs act as antagonists to calcium‐sensing receptors . Extracellular calcium activates the calcium‐sensing receptors to regulate the PTH secretion in parathyroid cells.…”
Section: Current Osteoporosis Treatmentmentioning
confidence: 99%
“…Calcilytic drugs act as antagonists to calcium-sensing receptors. 210 Extracellular calcium activates the calcium-sensing receptors to regulate the PTH secretion in parathyroid cells.…”
Section: Calcilytic Drugmentioning
confidence: 99%
“…Throughout this review, we have mentioned that osteocytes are the key producers of RANKL, DKK-1 and SOST-1 in adult bone. As the most abundant bone cell, osteocytes may be interesting drug targets, through the use of novel anti-resorptive and anabolic agents and monoclonal antibodies against osteocyte-associated sclerostin (AMG 785 or romozumab) [114]. These agents are currently under clinical trials for osteoporosis; however, a greater need for research in osteocytes in the area of bone metastasis is desired.…”
Section: Resultsmentioning
confidence: 99%
“…Many of them have an important role in bone. Among them are Insulin -Like Growth Factor-I (IGF-I) and II (IGF-II) -both involved in bone formation and Transforming Growth Beta Factor (TGF-B) -insociated in bone formation and resorption [20,32].…”
Section: N Growth Factormentioning
confidence: 99%